195 results about "Lipoprotein cholesterol" patented technology

Methods for assessing the risk of developing Type 2 diabetes and other related disorders include obtaining an NMR derived reference spectrum for a known glucose concentration sample and storing this information as a reference standard. A patient blood sample is collected and NMR derived patient spectrums for the blood sample are obtained. The two NMR data sets (the reference and the patient) are compared and a glucose concentration is determined for the patient sample. The glucose concentration can be evaluated with a blood sample undergoing lipoprotein cholesterol evaluation. The NMR based test can be used to concurrently provide a glucose concentration and lipoprotein constituent values based on a single testing event. The disclosure also includes a multi-purpose test, i.e., a test which concurrently provides lipoprotein screening and coronary heart disease risk evaluation along with a diabetes screening and risk assessment for developing Type 2 diabetes. A method for assessing diabetes includes identifying the presence of diabetic dyslipidemia based on the values of predetermined NMR measured lipoprotein constituents.

The invention discloses a composition of probiotic fermented horseradish tree leaves as well as a preparation method and application of the composition. The preparation method comprises the following steps: crushing and immersing horseradish tree leaves; adding glucose, peptone, yeast extract, yeast powder and inorganic salt into an immersing solution; extracting at a high pressure; and after carrying out probiotic fermentation and centrifuging, adding polydextrose and fructo-oligosaccharide syrup and sterilizing to obtain the composition of the probiotic fermented horseradish tree leaves. The composition can be used for preparing health products, foods and beverages capable of lowering blood fat and improving a sleeping function. An experiment shows that the composition of the probiotic fermented horseradish tree leaves can be used for reducing the contents of total cholesterol (TC) and triglyceride (TG) in blood serum, and improving the content of high density lipoprotein cholesterol (HDL-C) in the blood serum; the composition of the probiotic fermented horseradish tree leaves, disclosed by the invention, has a function of lowering a blood fat level.

The invention relates to a kit for measuring high-density lipoprotein cholesterol. The kit comprises a first reagent and a second reagent, wherein the first reagent comprises a surface active agent I used for inhibiting the dissolution of non-high-density lipoprotein (NHDL), and a surface active agent II used for dissolving high-density lipoprotein (HDL); after the surface active agent I is mixed with the surface active agent II, the value of hydrophile-lipophile balance (HLB) is within the range of 13-14; the volume ratio of the surface active agent I to the surface active agent II in the first reagent is (1:30)-(1:1). Due to the synergistic effect of components, the stability of the kit is improved, and the HDL can be specifically released; furthermore, the dissociation of the NHDL can be specifically masked and inhibited, the interference of other components in serum can be eliminated, and the accuracy of measurement is guaranteed.

A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in mammalian subject is accomplished by intravenously administering to a mammalian subject, a therapeutically effective amount of a liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. The liposomal suspension is administered over a period of time, whereby in the levels of some or all of blood glucose, insulin, total cholesterol, LDL cholesterol, triglyceride, creatine kinase (CK), creatine kinase-MB (CK-MB), Hb-A1_c, lipoprotein (a), SGOT and SGPT fall back within the normal range or are significantly reduced.

A reagent for the content of the high density lipoprotein cholesterol in the quantitative determining serum sample, consists of the reagent I and reagent II that places respectively, the reagent I contains the heteropolymer anion compound, the divalency cation salt and the decentralized surfactants; the reagent II contains the styrylphenol polyoxyethylene ether. The invention provides a reagent box with the reagent I and the reagent II, and a method for determining the high density lipoprotein cholesterol content.

A 2,3,5,4'-tetrahydroxy distyrene-2-O-beta-D-glucoside used for hypoglycemic medicine is prepared from the decoction of fleece flower root through extracting, separating and purifying. It can suppress the increasement of serum cholesterol, decrease low-density serum lipoprotein cholesterol and improve activity of liver esterase.

A composition is provided which contains policosanol and B vitamins and which may be used for treating and or reducing hypercholesterolemia and hyperhomocysteinemia diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, homocysteine, coronary heart disease (heart attacks and strokes), carotid artery disease, inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, anxiety, depression, neurodegenerative disorders (such as but not limited to Alzheimers), and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and B vitamins which together effectively lower the risk of heart disease. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to B vitamins.

The invention discloses compound nutritional noodles and a preparation method thereof. The compound nutritional noodles are prepared by taking perilla frutescens, se-enriched mushrooms and buckwheat as main raw materials, wherein the organic selenium content of the compound nutritional noodles reaches 200 mu g/kg, and the alpha linolenic acid content of the compound nutritional noodles reaches 2%. The preparation method comprises the steps of: (1) preparation of se-enriched mushroom powder or se-enriched malt powder; (2) preparation of perilla frutescens pulp; (3) preparation of buckwheat powder; (4) determination of a formula of the nutritional noodles; and (5) preparation of the noodles. Research proves that due to the reasonable collocation of the perilla frutescens pulp, the se-enriched mushroom powder or the se-enriched malt powder and the buckwheat powder, strong nutrition and health care functions can be brought into play in the aspects of regulating the fat metabolism, enhancing the immunoregulation, reducing the high blood fat and low-density lipoprotein cholesterol, eliminating lead and detoxifying, protecting the liver and heart and blood vessels, and the like. Therefore, the compound nutritional noodles disclosed by the invention have the function of compound nutrition, increase the diet varieties, and can promote the health of people. The compound nutritional noodles are suitable for adults and children to eat.

The invention discloses an application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and/or medicines. The lactobacillus rhamnosus CCFM1060 can tolerate thegastrointestinal environment of the human body, significantly improve fasting blood glucose rise and abnormal oral glucose tolerance of type 2 diabetics caused by high fat diet and STZ injection, reduce the area under the curve during glucose tolerance drug administration, and relieve insulin resistance; remarkably improve the increase of total cholesterol content and the increase of low-density lipoprotein cholesterol in serum of type 2 diabetics caused by high-fat diet and STZ injection; obviously relieve the inflammatory state of the liver; and significantly reduce pancreatic and liver pathological injuries caused by high-fat diet and STZ injection. The lactobacillus rhamnosus CCFM1060 has relatively strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving the toxicity of the PFOA.

The invention discloses a method and reagent for detecting small and dense low-density lipoprotein cholesterol (sdLDL-C) in a sample. The method is characterized by comprising the steps of (1) eliminating cholesterol, except the sdLDL-C, in lipoproteins in the sample first in the presence of cholesterol esterase and an ion selective agent; and (2) conducting quantitative detection on remaining sdLDL-C obtained after treatment in step (1). The ion selective agent is used to selectively eliminate lipoproteins other than the sdLDL-C, so as to detect the sdLDL-C.

A lipid-lowering tea and a production method relate to the production process of bagged tea. The invention mainly comprises raw hawthorns, cassia seeds, lotus leaves and black tea. The invention can obviously inhibit the increase of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and atherosclerosis index (CAI) of serum, improve the high-density lipoprotein cholesterol (HDL-C) and anti-atherogenic index (AI), prevent fatty liver degeneration, slow and inhibit the formation of atherosclerotic plaque. The tea is of food class, which ensures the taste and has the specific effect; long-term tea drinking causes no toxic side effects; besides, the lipid-lowering tea is convenient and can be used in daily life, working, tourism and leisure time, and the user can enjoy health-care in tea drinking.

The invention discloses application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and/or medicines. The bifidobacterium adolescentis CCFM1061 can be rapidly colonized in the intestinal tracts, can remarkably improve fasting blood glucose and oral glucose tolerance of type 2 diabetes induced by STZ and high-fat diet and decrease the area under a curvewhen glucose tolerance is reduced, can remarkably alleviate the increase of total cholesterol and the decrease of high-density lipoprotein cholesterol in serum of the type 2 diabetes caused by STZ and high-fat diet, can remarkably alleviate the insulin resistance of the type 2 diabetes, can remarkably improve the level of inflammation in liver tissues of the type 2 diabetes, and can remarkably alleviate the pathological damage of the pancreas, liver and other tissues of the type 2 diabetes. In addition, the bifidobacterium adolescentis CCFM1061 has strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving PFOA toxicity.

This invention provides a process for extracting the flavonoid and alkaloid components from lotus leaf and provides a method for the reduction of body weight, total cholesterol (TC), low density lipoprotein (LDL) cholesterol, and triglycerides (TG). It also provides a method for increasing high density lipoprotein (HDL) cholesterol and the prevention of coronary heart disease (CHD). There are 10% to 80% flavones and 10% to 80% alkaloids in the lotus leaf extract powder of this invention. This process produces an improved standardized raw material that may be utilized as a single dietary supplement, food additive, or medicine and it may be added to other plant extracts, nutraceuticals, or pharmaceuticals.

The invention discloses a high-performance small and dense low-density lipoprotein cholesterol detection kit. The kit comprises the following raw materials in parts by weight; a reagent A: 90 to 110 mmol/L of a Good's buffer solution; 1-3 ku/L of cholesterol esterase, 1-2 ku/L of cholesterol oxidase, 0.7-0.9 ku/L of phospholipase, 400-600 ku/L of catalase, and 1-3 mmol/L N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline sodium salt (TOOS); and a reagent B: 90-110 mmol/L of the Good's buffer solution, 2-3 ku/L of peroxidase, 3-5 mmol/L of 4-aminoantipyrine and 0.04-0.06% of sodium azide. Theinvention relates to the technical field of lipoprotein cholesterol detection, and discloses the high-performance small and dense low-density lipoprotein cholesterol detection kit. The non-sdLDL-C components are removed through cholesterol lipase, cholesterol oxidase, phospholipase and catalase; the interference of other lipoprotein cholesterol on the detection process is avoided, the capacity ofthe small and dense low-density lipoprotein cholesterol in serum can be directly determined by using a full-automatic biochemical analyzer, and the kit is suitable for the requirements of clinical andlaboratory on the determination of the content of the small and dense low-density lipoprotein cholesterol.

The invention discloses a kit for detecting small and dense low-density lipoprotein cholesterin. The kit is characterized by comprising polyoxyethylene fatty acid ester, cholesterol esterase, cholesterol oxidase, dodecyl polypeptide and triton X-100, wherein the small and dense low-density lipoprotein cholesterin in a serum sample is protected under the action of the polyoxyethylene fatty acid ester, reaction of the small and dense low-density lipoprotein cholesterin with the cholesterol esterase and the cholesterol oxidase is inhibited to a certain extent, and the other lipoprotein cholesterols react with the cholesterol esterase and the cholesterol oxidase under the action of the dodecyl polypeptide to be eliminated; and the triton X-100 reacts with the remaining small and dense low-density lipoprotein cholesterin to detect the content thereof. The kit can be used for quickly and conveniently detecting sdLDL-C in the serum sample. The reagent formula is simple and easy to prepare and low in cost, large-scale industrial preparation can be carried out, and meanwhile, the kit is capable of efficiently, accurately and specifically detecting the small and dense low-density lipoprotein cholesterin in the sample.

The invention provides application of PCSK9-targeted microRNA or a drug composition containing the same in preparing drug for inhibiting PCSK9 protein level. In addition, the invention further relatesto a drug composition for treating low-density lipoprotein cholesterol related metabolic disease. The drug composition comprises (a) drug in effective treatment amount and clinically for treating thelow-density lipoprotein cholesterol related metabolic disease and (b) PCSK9-targeted microRNA or the drug composition containing the same in effective treatment amount. Experiments verify that 31 types of microRNA can inhibit PCSK9 protein level in liver cells or liver cell culture liquid, thereby being capable of lowering level of LDLC so as to treat the LDLC related metabolic disease.

The invention provides an efficient and specific small and compact low-density lipoprotein cholesterol detection kit. The kit is a liquid dual reagent and consists of a reagent R1 and a reagent R2 according to the volume ratio of 3: 1. A polymer combination including 3-benzyloxy phenyl ether, polyoxyethylene alkyl ether and PEG800 in the efficient and specific small and compact low-density lipoprotein cholesterol detection kit serves as an important composition in the reagent R1 to fully eliminate influences of lipoprotein cholesterol except for sdLDL-C in a to-be-detected sample to sdLDL-C detection well; and moreover, in the reagent R2, by addition of a denaturant Triton X-100, protected sdLDL-C in the to-be-detected sample is released, thus, only sdLDL-C is detected efficiently and specifically, and accuracy of a detecting result is ensured.

The invention provides a lipoprotein cholesterol determination reagent and a kit, belonging to the technical field of biochemical detection. The reagent comprises poly-alpha-olefin, cholesterol oxidase and reaction promoter, and further comprises cholesterol esterase, peroxidase, catalase, catalase inhibitor, surface active agent, emulsifier, polyanion, divalent cation, stabilizer, anti-interference agent, color developing agent and preservative. The reagent and the kit provided by the invention can be used for full-automatic biochemical analyzer detection, are simple and convenient to operate, can improve detection efficiency and accuracy and can reduce detection cost.

The invention relates to an antrodia camphorate composition. The composition is prepared from the following components in parts by weight: 100-135 parts of antrodia camphorate mycelia, 12-18 parts of coenzyme Q10, 15-30 parts of gynostemma pentaphylla, 20-35 parts of pseudo-ginseng, 5-12 parts of American ginseng, 3-6 parts of wolfberry fruits and 20-40 parts of olive extract. The antrodia camphorate composition can be used for lowering the contents of total blood serum cholesterol, low-density lipoprotein cholesterol and triglyceride and improving the content of high-density lipoprotein cholesterol; the liver damage can be reduced and the liver function can be improved; and the antrodia camphorate composition has the effects of activating blood and removing blood stasis, lowering blood pressure and preventing cardiovascular and cerebrovascular events, and also has the effects of lowering blood glucose, improving the immunity and resisting tumors.

The invention provides application of monascus color components and derivatives thereof in preparing drugs for preventing and treating cardiovascular and cerebrovascular diseases, belonging to the technical field of monascus compound application. The series compound comprises rubropunctamine, monascorubramine, monascin, ankaflavin, rubropunctatin, monascorubrine, monasfluore A, monasfluore B and derivatives thereof. The compound has the functions of reducing triglyceride, total cholesterol and low density lipoprotein cholesterol and elevating high density lipoprotein cholesterol and can be used as the drug and health care product additive for preventing and treating cardiovascular and cerebrovascular diseases.

The invention discloses natural medicine composition for adjusting diabetes immune and metabolism functions and a preparation method of the natural medicine composition. The natural medicine composition comprises raw materials as follows: cordyceps militaris, cyclocarya paliurus leaves and ginkgo biloba extract. A pharmacology experiment proves that the level of TG (triacylglycerol), TC (total cholesterol) and LDL-C (low-density lipoprotein cholesterol) in serum of a db/db diabetic mouse can be remarkably reduced and indicates that a product researched by our company has a remarkable function of adjustment of fat metabolism and can effectively protect the liver and the kidneys. According to compatibility of medicines, immunity declining and glucolipid metabolism disorder caused by diabetes are taken as pointcut, the functions of immunity boosting and metabolic regulation of cordyceps militaris, cyclocarya paliurus and the ginkgo leaves are used for research of health-care food, and a certain scientific theoretical foundation is provided.

The invention discloses lactobacillus reuteri CCFM1178 capable of intervening in metabolic syndrome, and application, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1178 screened by the invention can obviously eliminate increase of the serum total cholesterol content and the low-density lipoprotein cholesterol of a mouse with the metabolic syndrome caused by high fat diet, relieve the increase of the body weight of an individual with the metabolic syndrome, and reduce daily diet intake and energy conversion efficiency; the intestinal flora imbalance of the mouse due to high fat is eliminated; and the levels of proinflammatory factors IL-6 and TNF-[alpha] in the liver of the mouse with the metabolic syndrome are improved, and the level of an anti-inflammatory factor IL-10 is improved to prevent the metabolic syndrome, inhibit serum lipopolysaccharide endotoxin and maintain a colon barrier structure. The lactobacillus reuteri CCFM1178 disclosed by the invention can be used for preparing medicines or functional foods for relieving diseases such as the metabolic syndrome, the non-alcoholic fatty liver disease, the diabetes mellitus and the like, and has a very wide application prospect.